Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
225000 211500 211000 209000 214000 Last
566162 1426174 671761 475696 870748 Volume
+0.90% -6.00% -0.24% -0.95% +2.39% Change
Estimated financial data (e)
Sales 2021 1 904 B 1,60 B 1,60 B
Net income 2021 586 B 0,49 B 0,49 B
Net cash position 2021 246 B 0,21 B 0,21 B
P/E ratio 2021 51,3x
Yield 2021 0,01%
Sales 2022 2 301 B 1,93 B 1,93 B
Net income 2022 743 B 0,62 B 0,62 B
Net cash position 2022 884 B 0,74 B 0,74 B
P/E ratio 2022 40,3x
Yield 2022 0,01%
Capitalization 29 238 B 24 431 M 24 501 M
EV / Sales 2021 15,2x
EV / Sales 2022 12,3x
Nbr of Employees 2 034
Free-Float 76,0%
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical... 
More about the company
Ratings of Celltrion, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CELLTRION, INC.
11/15Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First M..
AQ
11/15Celltrion Inc. Shares Rally After EU Approves Marketing of Its Covid-19 Treatment
DJ
11/15European Commission Approves Celltrion's Antibody COVID-19 Treatment
MT
11/15Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
CI
11/15S.Korea stocks end 1% higher on chip, biopharma boost, U.S. data in focus
RE
11/15S&P Upgrades ITV To Stable From Negative On Expected Revenue Recovery
MT
11/12EC Formally Authorises COVID-19 Drugs From Regeneron-Roche, Celltrion
RE
11/11EU Drug Regulator Backs COVID-19 Therapy from South Korea's Celltrion
MT
11/11Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First M..
CI
11/11South Korea's Kospi Closes Lower as Inflation Hits Three-Decade High in US; Celltrion L..
MT
11/10Celltrion's Net Profit Plunges 20% in Q3
MT
11/10CELLTRION : 3Q 2021 Earnings Release_Celltrion Inc.
PU
11/09EU Poised To Approve Two COVID-19 Antibody Drugs
MT
11/09Amid spike in cases, EU to shortly approve first COVID antibody drugs - sources
RE
11/09Amid spike in cases, EU to shortly approve first COVID antibody drugs - sources
RE
More news
News in other languages on CELLTRION, INC.
11/23MÄRKTE ASIEN/Hongkong schwach - Sydney freundlich
11/16MÄRKTE ASIEN/Börsen im Wartemodus uneinheitlich
11/16MÄRKTE ASIEN/Hongkong fest - Sydney schwächer
11/15MÄRKTE ASIEN/Etwas fester - Chinas Börsen hinken hinterher
11/15MÄRKTE ASIEN/Uneinheitlich - Anleger warten auf Xi Jinping und Biden
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | A068270 | KR7068270008 | MarketScreener
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 214 000,00 KRW
Average target price 287 437,50 KRW
Spread / Average Target 34,3%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-40.39%24 431
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
ALNYLAM PHARMACEUTICALS, INC.45.06%22 548